News
OVID
3.100
+3.68%
0.110
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NASDAQ · 9h ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. Syra Health stock rose 14.96% during the session. Sage Therapeutics and Evotec were among the losers in the day's trading.
Benzinga · 2d ago
Weekly Report: what happened at OVID last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at OVID last week (0408-0412)?
Weekly Report · 04/15 09:19
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Ovid Therapeutics Inc. Will release results from two phase 3 studies, using soticlestat for the treatment of patients with two rare forms of epileptic disorders in late 2024. The drug is being co-developed with Takeda Pharmaceutical to tackle Lennox-Gastaut Syndrome and Dravet Syndrome. The company has another drug in the pipeline being developed to treat chronic seizures. Ovid is expected to release data from these two studies in Q3 of 2024.
Seeking Alpha · 04/09 14:48
Weekly Report: what happened at OVID last week (0401-0405)?
Weekly Report · 04/08 09:20
Ovid Therapeutics gains on bullish view at Wedbush
Ovid Therapeutics (NASDAQ:OVID) traded higher on Friday after Wedbush launched its coverage with an Outperform recommendation. The company's therapeutic pipeline is dominated by small molecules. Soticlestat is an oral medicine currently undergoing late-stage trials for epilepsy.
Seeking Alpha · 04/05 17:53
OVID THERAPEUTICS INC <OVID.O>: WEDBUSH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $8
Reuters · 04/05 11:29
Ovid Therapeutics Initiated at Outperform by Wedbush
Dow Jones · 04/05 09:03
Ovid Therapeutics Price Target Announced at $8.00/Share by Wedbush
Dow Jones · 04/05 09:03
Wedbush Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $8
Benzinga · 04/05 08:53
Weekly Report: what happened at OVID last week (0325-0329)?
Weekly Report · 04/01 09:20
Weekly Report: what happened at OVID last week (0318-0322)?
Weekly Report · 03/25 09:20
Insider Buys Additional US$50k In Ovid Therapeutics Stock
Jeremy Levin, the President of Ovid Therapeutics Inc. Recently bought US$50k worth of shares at US$2.76 per share. It is the biggest insider purchase in the last year. The company's insider ownership of 5.2% of the company is good to see. Jeremy Levin was the only individual to buy shares in OvidTherapeutics over the last 12 months. You can see the insider transactions at Ovidtherapeutics in the table below. Ovid therapeutics is currently trading on the NASDAQ.
Simply Wall St · 03/22 10:03
Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Dow Jones index closed higher by over 400 points on Wednesday. Insider transactions for penny stocks indicate confidence or concern around the company's prospects. NextNav Inc. And Ovid Therapeutics Inc. Have recently had notable insider transactions for their shares. Eyenovia reported worse-than-expected fourth-quarter financial results.
Benzinga · 03/21 10:45
Weekly Report: what happened at OVID last week (0311-0315)?
Weekly Report · 03/18 09:20
Ovid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic Partnerships
TipRanks · 03/12 10:45
Institutional investors may overlook Ovid Therapeutics Inc.'s (NASDAQ:OVID) recent US$28m market cap drop as long-term gains remain positive
Institutional investors own 32% of Ovid Therapeutics Inc. (NASDAQ:OVID) The top 7 shareholders own 53% of the company. Takeda Pharmaceutical Company Limited is the largest shareholder with 11% of shares. OvidTherapeutics has a large amount of shares in the company, but the stock is vulnerable to insider selling. The company's ownership of 32% could be a concern for the company's future growth. It's also worth looking at the past earnings history of the firm.
Simply Wall St · 03/12 10:03
Ovid Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Ovid Therapeutics Inc reports results for the quarter ended in December. Revenue rose 206.8% to $142.00 thousand from a year ago. The company reported a quarterly adjusted loss of 22 cents per share. The mean expectation of seven analysts was for a loss of 5 cents.
Reuters · 03/11 13:32
Weekly Report: what happened at OVID last week (0304-0308)?
Weekly Report · 03/11 09:19
More
Webull provides a variety of real-time OVID stock news. You can receive the latest news about Ovid Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.